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ABSTRACT
Objectives: To evaluate the adequacy of reporting of
protocols for randomised trials on diseases of the
digestive system registered in http://ClinicalTrials.gov
and the consistency between primary outcomes,
secondary outcomes and sample size speciﬁed in
http://ClinicalTrials.gov and published trials.
Methods: Randomised phase III trials on adult
patients with gastrointestinal diseases registered
before January 2009 in http://ClinicalTrials.gov were
eligible for inclusion. From http://ClinicalTrials.gov all
data elements in the database required by the
International Committee of Medical Journal Editors
(ICMJE) member journals were extracted. The
subsequent publications for registered trials were
identiﬁed. For published trials, data concerning
publication date, primary and secondary endpoint,
sample size, and whether the journal adhered to ICMJE
principles were extracted. Differences between primary
and secondary outcomes, sample size and sample size
calculations data in http://ClinicalTrials.gov and in the
published paper were registered.
Results: 105 trials were evaluated. 66 trials (63%)
were published. 30% of trials were registered
incorrectly after their completion date. Several data
elements of the required ICMJE data list were not ﬁlled
in, with missing data in 22% and 11%, respectively, of
cases concerning the primary outcome measure and
sample size. In 26% of the published papers, data on
sample size calculations were missing and
discrepancies between sample size reporting in http://
ClinicalTrials.gov and published trials existed.
Conclusion: The quality of registration of randomised
controlled trials still needs improvement.
INTRODUCTION
Since 2005, the International Committee of
Medical Journal Editors (ICMJE) has initi-
ated a policy requiring investigators to
register clinical trials on healthcare inter-
ventions in a public trial registry as a condi-
tion for consideration for publication.
1
http://ClinicalTrials.gov and similar clinical
trial registries available through the WHO
International Clinical Trials Portal are classed
as acceptable. Trials must register at or before
the onset of patient enrolment. The regis-
tration should include information about the
trial design. The registration policy is appli-
cable to any trial starting enrolment after 1
July 2005. For trials that began enrolment
prior to this date, the ICMJE member jour-
nals originally required registration by 13
September 2005.
1 However, beginning on 13
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ARTICLE SUMMARY
Article focus
- Outcome reporting bias is a considerable
problem.
- A number of journals (International Committee of
Medical Journal Editors journals) only publish
clinical trials that are registered in relevant trial
databases such as http://ClinicalTrials.gov before
recruitment of participants. Older trials
commenced after 1 July 2005 will be considered
for publication only if they are adequately
registered before journal submission.
- Previous studies of published trials suggest that
many are registered inadequately.
Key messages
- A number of trials are registered inadequately in
http://ClinicalTrials.gov without information
about basic methodological issues.
- Several trials published in journals that require
registration in online databases are registered
after their date of completion.
- Discrepancies between the registered informa-
tion in trial registrations and the trial publications
still exist (such as the planned sample size
calculations).
Strength and limitations of this study
- The study is small, only evaluating 105 trials. The
real extent of inadequate trial registration may be
under- or overestimated.
- Only trials concerning gastrointestinal diseases
were evaluated, which makes it difﬁcult to
generalise to other medical specialties.
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Open Access ResearchSeptember 2005, ICMJE journals will consider such trials
only if they are adequately registered before journal
submission.
2 Trials are only eligible for publication in
ICMJE journals if registered correctly.
The purpose of trial registries is to reduce the risk of
dissemination and reporting bias and to ensure that
clinicians, researchers and patients can ﬁnd key infor-
mation about every clinical trial whose principal aim is to
shape medical decision-making. Overviews of published
trials suggest that the registration of several trials is
inadequate.
3e11 Likewise, the quality and completeness
of trial registration in speciﬁc trial registries have been
found inadequate.
51 1Inadequate registration will not
reduce the risk of bias, but will give the reader and
journals a false impression of adequate bias control.
The objective of this study was to evaluate the
adequacy of reporting of randomised trials on diseases of
the digestive system registered in http://ClinicalTrials.
gov and to evaluate the consistency between primary
outcomes, secondary outcomes and sample size speciﬁed
in trial protocols and published trials.
METHODS
The present work is based on a written protocol, which is
included as a supplementary ﬁle to the paper at BMJ
Open.
Identiﬁcation of eligible trials
To obtain a homogenous sample, and as all authors have
a special interest in gastroenterology and hepatology, we
focused on phase III trials on adult patients with diseases
in the digestive system. To achieve a larger proportion of
trials with subsequent publication, trials registered after
January 2009 were not included. Accordingly any rand-
omised trial on adult patients with gastrointestinal
diseases registered before January 2009 in http://
ClinicalTrials.gov was eligible for inclusion.
Eligible trials were identiﬁed through electronic
searches in http://ClinicalTrials.gov using the search
strategy: closed studies | interventional studies | digestive
system disease | adult senior | phase III | updated on or
before 1 January 2009. Subsequent publications of clin-
ical trials were identiﬁed through electronic searches in
PubMed, Medline, Embase, Science Citation Index and
the Cochrane Library using investigator names and
keywords.
Data extraction
The adequacy of reporting of protocols was assessed
through data extracted from the http://ClinicalTrials.
gov database and their subsequent publications. Initially,
all trials identiﬁed through the electronic search in
http://ClinicalTrials.gov were listed and two authors
evaluated whether the trials fulﬁlled the inclusion
criteria. Excluded trials were listed with the reason for
exclusion. The authors independently extracted data
from included trials based on pilot tested data extraction
forms. Disagreements between authors were resolved
through discussion before analysis.
Data extracted from http://ClinicalTrials.gov included
all data elements in the database required by the ICMJE
member journals (table 2). For each trial, the start
date, completion date and registration date in http://
ClinicalTrials.gov were recorded. Data extracted from
the published articles included publication date, journal
name and whether the journal adhered to ICMJE prin-
ciples. Primary and secondary outcome measures were
extracted; any differences between primary and
secondary outcomes speciﬁed in http://ClinicalTrials.
gov and those deﬁned in the published articles were
recorded, as was whether changes were reported. Finally
data regarding sample size and sample size calculation
were extracted, and potential differences between the
planned sample size and number of randomised patients
were recorded, as was whether discrepancies between
sample size data in http://ClinicalTrials.gov and in the
published paper were present.
Statistical analysis
Statistical analysis was performed using STATA V.10.0 for
Windows. Characteristics of included trials were
summarised as frequencies or medians with ranges. The
relation between key trial characteristics and whether
trials were published was assessed based on multiple
logistic regression analysis with results presented as ORs
with 95% CIs and p values. All tests were two tailed and p
values <0.05 were considered signiﬁcant.
Post hoc analysis
The proportion of published studies that identiﬁed
positive versus negative results was examined. We
deﬁned authors’ conclusions as the reported interpre-
tation of the extent to which the overall trial result
favoured the experimental over the control intervention.
We graded authors’ conclusions according to the
phrasing in the abstract and the summarised conclusion
on a previously validated six-point scale
12 13 (box 1).
Higher scores indicate a more positive conclusion
towards the experimental intervention: scores of 1e3
favoured the control and scores of 4e6 favoured the
experimental intervention.
RESULTS
Initially, we retrieved 150 references through our elec-
tronic search. After excluding trials that turned out to be
observational, trials that were not initiated (because of
lack of funding or for logistic reasons), and trials that
turned out to be safety studies in healthy participants, we
identiﬁed 105 trials that fulﬁlled our inclusion criteria.
The description of the included trials is presented in
table 1. The majority of trials assessed interventions for
malignant diseases, inﬂammatory bowel disease or liver
diseases. Most trials investigated drugs.
The included trials were registered in http://
ClinicalTrials.gov during 1998 to 2008 (median 2005).
Ninety-nine of the 105 trials provided information
regarding the date the trial was initiated (table 2). Based
on the registered data, the trials were initiated during
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Registration in ClinicalTrials.gov1978 to 2006 (median 2002). Seventy-six of the 99 trials
were initiated before 2005. Only 73 trials reported the
date the trial was completed. The date of completion
ranged from 1996 to 2009 (median 2006). Fifty-eight
(55%) trials were registered correctly according to ICMJE
criteria (ie, before or at the time of initiation for trials
conducted after 1 July 2005, and before 13 September
2005 for trials starting before 1 July 2005). Thirty-one
(30%) trials were registered after the trial was completed.
Of the 105 included trials, 23 (22%) did not describe
the primary outcome measures and 24 (32%) did not
describe the secondary outcome measures (table 2). In
two trials one of the initially registered outcome
measures was changed to a secondary outcome measure
(NCT00204750) and (NCT00606619). Secondary
outcomes were changed in three trials (some outcomes
were omitted and new outcomes introduced). However,
for several trials changes were difﬁcult to classify due to
the wording and non-speciﬁc deﬁnitions.
All 105 trials reported the study type, and provided
a brief title, design, condition, intervention, recruit-
ment, eligibility criteria and contacts. Twelve trials (11%)
did not report the planned number of patients enrolled
in the trial (table 2).
We identiﬁed published reports for 66 trials (63%), in
28 different journals. The trials were published during
1980 to 2011 (median 2008). Twelve of the 31 trials
registered after the completion date in http://
ClinicalTrials.gov were published after 2005 in journals
proclaiming to adhere to ICMJE principles (data not
shown). No changes were identiﬁed in the deﬁnitions of
the primary outcome measure between registrations in
http://ClinicalTrials.gov and the published reports
(table 3). Changes in the secondary outcomes were
Box 1 Equipoise scale
- Experimental intervention highly preferred and should
now be considered the standard intervention in all
patients or similar statement (6 points).
- Experimental intervention preferred to standard but
further trials still indicated; may be more costly or
similar disclaimer (5 points).
- Experimental and control intervention about equal but
experimental intervention successful because of minor
advantage (4 points).
- Experimental and control intervention about equal, but
experimental intervention disappointing as control inter-
vention had some minor advantage (3 points).
- Control intervention preferred to experimental interven-
tion but experimental intervention might be promising
under some circumstances or similar (2 points).
- Control intervention highly preferred and is best alterna-
tive; should be considered the standard intervention in all
patients or similar (1 point).
Table 1 Characteristics of 105 trials registered in http://
ClinicalTrials.gov
Characteristic Trials, no. (%)
Disease examined
Malignant disease 45 (43%)
Inﬂammatory bowel disease 16 (15%)
Viral hepatitis 11 (10%)
Gastro-oesophageal reﬂux
disease
6 (6%)
Liver (autoimmune and
cirrhosis)
8 (8%)
Other diseases 19 (18%)
Experimental intervention
Drugs 86 (82%)
Surgery 12 (11%)
Other interventions 7 (7%)
Control group intervention
Drugs 50 (47%)
Placebo or no intervention 40 (38%)
Surgery 10 (10%)
Other intervention 5 (5%)
Funding source
Proﬁt 62 (59%)
Non-proﬁt 38 (36%)
Proﬁt and non-proﬁt 3 (3%)
Not reported 2 (2%)
Table 2 Data extracted from 105 trials in http://
ClinicalTrials.gov
No. reported
(%)
No. not
reported
(%)
Tracking information
Registration date in
http://ClinicalTrials.gov
105 (100%) 0
Study start date 99 (94%) 6 (6%)
Completion date 73 (70%) 32 (30%)
Primary outcome measures* 82 (78%) 23 (22%)
Secondary outcome
measuresy
71 (68%) 34 (32%)
Descriptive information
Brief title 105 (100%) 0
Ofﬁcial title 102 (97%) 3 (3%)
Study type 105 (100%) 0
Study design 105 (100%) 0
Condition 105 (100%) 0
Intervention 105 (100%) 0
Recruitment information
Recruitment status 105 (100%) 0
Enrolment number 93 (89%) 12 (11%)
Eligibility criteria 105 (100%) 0
Location countriesz 85 (81%) 20 (19%)
Administrative information
NCT ID 105 (100%) 0
Study sponsor 103 (98%) 2 (2%)
Collaborators 45 (43%) 60 (57%)
Investigators 90 (86%) 15 (14%)
*Changes in primary outcome measures were recorded in two
trials.
yChanges in secondary outcome measures were recorded in three
trials.
zSome sponsors remove location information once a trial closes to
recruitment.
3
Wildt S, Krag A, Gluud L. BMJ Open 2011;2:e000309. doi:10.1136/bmjopen-2011-000309 3
Registration in ClinicalTrials.govidentiﬁed for six trials and primarily included intro-
duction of additional outcomes (eg, compliance) or
omission of outcomes (eg, quality of life). Of the 66 trials
that were published, 49 (74%) described sample size
calculations in the published report. Based on the
published trial reports, nine trials did not reach the
planned sample size due to unexpectedly low recruit-
ment rates, or because the trial was terminated early
after promising or disappointing interim analyses. For
seven trials, discrepancies between the planned sample
size registered in http://ClinicalTrials.gov and the
number of patients randomised based on the published
reports were identiﬁed without any apparent explana-
tion. In four cases the number of patients in the preset
sample size and/or the number of patients randomised
were less in the published report than the sample size
speciﬁed in the trial registry. In three cases the preset
sample size and/or randomisation number were higher
in the published reports than speciﬁed in the trial
registry. The number of participants in the included
trials ranged from 16 to 1135 (median 305). The
difference ranged from 545 participants fewer than
planned to 138 participants more than planned.
The planned sample size provided in http://Clin-
icalTrials.gov ranged from 36 to 1500 participants
(median 220) in trials that were published and from 30 to
660 (median 60) for trials that were not published. There
was no clear association between the reported planned
sample size reported in http://ClinicalTrials.gov and the
chance that the trial was published (OR 1.01; 95% CI 1.00
to 1.01). There was no apparent association between
publication and registrations in http://ClinicalTrials.gov
of the primary outcome measure (OR 0.80; 95% CI 0.29
to 2.17) or the secondary outcome measure (OR 0.58;
95% CI 0.224 to 1.44).
In most published trials authors’ conclusions favoured
the experimental intervention (ﬁgure 1).
DISCUSSION
The results of this study suggest that the reporting of
data in the public trial registry http://ClinicalTrials.gov
is inadequate. First, 30% of the trials analysed were
registered after the completion date. Second, several
data of the required ICMJE data list were not ﬁlled in,
with missing data in 22% and 11%, respectively, of cases
concerning the important issues primary outcome
measures and sample size. Third, only 63% of the
analysed trials registered were published. Several articles
(26%) lacked sample size calculations and there were
discrepancies between sample size reporting in http://
ClinicalTrials.gov and published trials.
One of the purposes of reporting protocols in a clin-
ical trial registry is to improve the quality of reporting of
biomedical research. The policy of registration of
protocols at the start or before termination of the study
is to minimise the likelihood of authors introducing bias
into their papers by making major changes that other-
wise might remain undisclosed and undetectable.
14 We
were surprised to see that about a third of trials exam-
ined in our study were registered after the completion
date; this kind of registration seems inappropriate or
irrelevant and is a challenge to the credibility of the
registers. Registration after the study is complete gives
the reader a false sense of security since the published
information in the journal only consists of the trial
registration number. In one study (NCT00766805) that
was registered post hoc both number of patients and
number of events differed from a previously published
abstract. These changes in the numbers and outcomes
altered the conclusions of a meta-analysis on the
subject.
15 Such changes clearly hamper the validity of
trials, however it is not possible to trace and document if
the trials are not registered correctly. Since the require-
ments regarding trial registration have been established
for several years, investigators have had time to get
acquainted with the procedures. In most submission
procedures for randomised clinical trials, journals ask
authors to provide their registration number but not the
date. Providing the date of registration and the start and
completion dates for the trial would provide a better
overview than just the registration number.
Bias in trial registry has previously been demonstrated.
Zarin et al and Ross et al found that the primary outcome
measure ﬁeld in http://ClinicalTrials.gov was completed
in 66e89% of cases.
5 11 These data correspond to our
ﬁndings, which show that 78% of trials provided infor-
mation regarding their primary outcome measure.
However, this also means that several trials still lack
Table 3 Characteristics of 66 published trials from
a sample of 105 trials registered in http://ClinicalTrials.
govdconcerning changes in outcome measures and
sample size
Changes in primary outcome measures 0
Changes in secondary outcomes measures 6 (9%)
Sample size calculation reported in article 49 (74%)
Planned sample size not randomised,
but described
9 (13%)
Difference between planned enrolment
registered in http://ClinicalTrials.gov and
sample size calculation in published paper
7 (11%)
Figure 1 Equipoise scale, authors’ scores for conclusions in
66 published trials.
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Registration in ClinicalTrials.govcrucial information regarding basic components. Like-
wise it has previously been found that changes in sample
size exist between protocols and articles, and that
statistically signiﬁcant outcomes were favoured in being
fully reported.
31 6In this study we did not examined
whether outcome-reporting bias favoured signiﬁcant
primary outcomes, but we did ﬁnd that studies in favour
of the experimental intervention were published more
frequently than studies in favour of the control inter-
vention. On the positive side, we did not ﬁnd any
discrepancies between the data in the trial registration
and in published papers concerning primary outcome
measures. We did, however, ﬁnd changes concerning
secondary outcome measures. These discrepancies
suggest that post hoc changes are being made to the trial
protocols after the trial is initiated. None of the publi-
cations provided any explanations regarding the under-
lying reasons for the discrepancies.
In the present study, we found disagreements between
the sample size calculations reported in the trial registry
and the subsequent trial publications in seven cases.
Since discrepancies were identiﬁed for registrations that
were made for trials that were already running, the data
suggest that alterations were made post hoc. As changes
in sample size might lead to changes in study power,
deviation from the planned sample size should be
explained in the article. Without this information, we
were unable to determine whether the trials were
continued beyond the originally intended size after
interim analyses, or stopped for some other reason, such
as lack of funding, lower than expected recruitment
rates or low event rates. Since we did not have informa-
tion from the authors, we were unable to analyse this
ﬁnding further.
Our study has its limitations. First, it is a small study
only evaluating 105 trials. http://ClinicalTrials.gov has
several thousands of trials registered, and consequently
the real extent of inadequate trial registration may be
under- or overestimated. Second, we only evaluated
phase III trials of gastrointestinal diseases, which makes
it difﬁcult to generalise to other medical specialties.
Third, we only found published articles from 66 of 105
trials. A greater proportion of trials may be or may
become published, as we did not contact the primary
investigator to double-check publication status; as some
studies were completed within the year of this study,
publication may be possible in the near future.
In conclusion, adequate registration is supposed to
protect against publication bias and to ensure that
clinicians, researchers and patients can ﬁnd key infor-
mation about clinical trials. Our ﬁndings emphasise that
inadequate reporting can make the transparency and
interpretation of randomised clinical trial results difﬁ-
cult and that timing and quality of registration of rand-
omised controlled trials still needs improvement. Editors
should be encouraged to enforce correct registration of
trials to be published.
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